During a Case-Based Roundtable® event, Thach-Giao Truong, MD, discussed how data from the CheckMate-067 and RELATIVITY-047 ...

Alexander I. Spira, MD, PhD, FACP, discusses the clinical implications of ctDNA for treatment decisions and monitoring in ...

In a live event, Vinay Minocha, MD, discusses the addition of darolutamide to androgen deprivation therapy for in patients ...

Pathologists supported by a new artificial intelligence tool outperformed Standard of Care/Gold standard in determining ...

MB-105, a first-in-class CD5-targeted CAR T-cell therapy, received FDA orphan drug designation for relapsed/refractory T-cell ...

Panelists discuss how health care providers can optimize quality-of-life and treatment outcomes for patients with ...

Panelists discuss how myelofibrosis progresses from its molecular and genetic origins through various clinical manifestations ...

Alec Kimmelman, MD, PhD, and Shridar Ganesan, MD, PhD, discuss the institution's new molecular oncology program.

The FDA granted priority review for belzutifan for treating advanced pheochromocytoma and paraganglioma, with a PDUFA date ...

Oral paclitaxel matched IV in progression-free survival but outperformed it in overall survival for second-line advanced gastric cancer.

The FDA approved trastuzumab deruxtecan for adult patients with unresectable or metastatic HER2-low or HER2-ultralow breast ...

Alan Tan, MD, discusses factors influencing the choice of immunotherapy plus tyrosine kinase inhibitor vs dual IO in patients ...